Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.38 |
| ▸ | BAD | Q92934 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4974071 | 0.96 | ALDH1A1 (0.43) | KDM4EALDH1A1MAPTGAAMEN1 | |
| SCHEMBL4971564 | 0.82 | SMN1; SMN2 (0.41) | KDM4EALDH1A1MAPTGAAMEN1 | |
| SCHEMBL28308270 | 0.79 | KDM4E (0.48) | KDM4EALDH1A1MAPTGAAL3MBTL1 | |
| SCHEMBL4976946 | 0.76 | KDM4E (0.39) | KDM4EALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL4973067 | 0.76 | MAOA (0.49) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL7765659 | 0.75 | SNCA (0.43) | MEN1KMT2A | |
| SCHEMBL6568351 | 0.75 | MAPT (0.67) | KDM4EALDH1A1MAPTGAAMEN1 | |
| SCHEMBL4974899 | 0.74 | ALDH1A1 (0.46) | KDM4EALDH1A1MAPTGAAKMT2A | |
| SCHEMBL31530726 | 0.73 | SNCA (0.38) | MEN1KMT2A | |
| SCHEMBL21468537 | 0.72 | KDM4E (0.47) | KDM4EALDH1A1MAPTGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384947-B2 | Fused tricyclic heterocycles useful for treating hyper-proliferative disorders | BAYER HEALTHCARE LLC (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384947-B2 | Fused tricyclic heterocycles useful for treating hyper-proliferative disorders | BAYER HEALTHCARE LLC (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384947-B2 | Fused tricyclic heterocycles useful for treating hyper-proliferative disorders | BAYER HEALTHCARE LLC (US) | 2008-06-10 | — | — | US | disclosed |
| US-20060287387-A1 | Fused tricyclic heterocycles useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-12-21 | — | — | US | disclosed |
| US-7144885-B2 | Fused tricyclic heterocycles useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-12-05 | — | — | US | disclosed |
| US-20050165042-A1 | Fused tricyclic heterocycles useful for treating hyper-proliferative disoroders | BAYER HEALTHCARE LLC | 2005-07-28 | — | — | US | disclosed |
| EP-1478639-A1 | FUSED TRICYCLIC HETEROCYCLES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2004-11-24 | — | — | EP | disclosed |
| WO-2003072566-A1 | FUSED TRICYCLIC HETEROCYCLES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287387-A1 | Fused tricyclic heterocycles useful for treating hyper-proliferative disorders | MKI67, CCNA2, CDK4 | KDM4E 3497/4885ALDH1A1 973/4885MAPT 2667/4885 |
| US-20050165042-A1 | Fused tricyclic heterocycles useful for treating hyper-proliferative disoroders | MKI67, CCNI, PCNA | KDM4E 3721/4885ALDH1A1 637/4885MAPT 2236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.